Combination Capecitabine (Xeloda) and ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel) Chemotherapy as Neoadjuvant Treatment of Locally Advanced, Operable Breast Cancer
- Determine the rate of pathological complete response (i.e., tumor completely gone) in
women with previously untreated, unresected, stage II-IIIB breast cancer treated with
neoadjuvant therapy comprising capecitabine and paclitaxel (albumin-stabilized
nanoparticle formulation) (Abraxane^®).
- Evaluate the safety of this regimen in these patients.
- Determine overall clinical response rate in patients treated with this regimen.
OUTLINE: Patients receive up to 4 courses of capecitabine and paclitaxel (nanoparticle
albumin-stabilized formulation) (Abraxane^®) in the absence of disease progression. Patients
then undergo definitive surgical resection of the tumor off study.
PROJECTED ACCRUAL: A total of 33 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Pathological complete response rate
Anita Aggarwal, DO, PhD
Washington Hospital Center
|Washington Cancer Institute at Washington Hospital Center||Washington, District of Columbia 20010|